Topiramate: uses in people with an intellectual disability who have epilepsy.
Topiramate can control seizures in people with ID, but watch for slowed thinking or mood shifts, especially when mixed with other seizure drugs.
01Research in Context
What this study did
Kerr (1998) wrote a narrative review about topiramate for epilepsy in people with intellectual disability. The paper pulls together early clinic reports and small studies. It does not give patient numbers or trial stats.
The goal was to see if the new drug controls seizures without hurting thinking or mood.
What they found
The review says topiramate can cut seizures and the side-effects are 'manageable'. The main worry is neuropsychiatric events like slow thinking or mood swings, especially when the person takes more than one seizure drug.
No exact counts are given.
How this fits with other research
Bennett et al. (1998) extends this picture. Their one-year study shows zonisamide helps fewer children with ID (41%) than typical kids (67%). The lower success rate warns you to expect slower titration and extra meds.
Farrant et al. (1998) also extends the story to gabapentin. Seizure reduction looks similar for kids with and without ID, but younger children with attention problems show more behavior side-effects.
Willemsen-Swinkels et al. (1998) and Iivanainen (1998) sound a matching alarm. Both 1998 reviews say older drugs like carbamazepine and phenytoin can spare or harm cognition. Together these papers create a safety theme: pick the drug that protects learning and behavior, not just stops seizures.
Pilgrim et al. (2000) supersedes Kerr (1998) two years later. The newer review folds topiramate into a wider epilepsy-ID update and still finds most papers focus on pills, not service quality.
Why it matters
If you work with adults or children who have both ID and epilepsy, add topiramate to your watch list. Track subtle drops in response speed, initiation, or mood after each dose hike. Pair your ABC data with nursing seizure logs so the team can link behavior changes to drug timing rather than assume 'problem behavior'.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Start a simple timing sheet that pairs seizure count with attention-to-task percentages after each topiramate increase.
02At a glance
03Original abstract
The novel anticonvulsant topiramate has been shown to have efficacy across a range of seizure types including both generalized and partial seizures in several well-designed randomized controlled trials. It has also been shown to be effective in atonic seizures associated with Lennox-Gastaut syndrome. Tolerability data show a tendency to neuropsychiatric side-effects, such as confusion and word finding difficulties, when topiramate is used in polytherapy; these side-effects are reduced in monotherapy usage. The efficacy and spectrum of seizures treated by topiramate suggests that it has an important role in managing epilepsy in people with intellectual disability. The predictable side-effects can be monitored in clinical practice and possibly reduced by slow dose increments. The data set of patients with intellectual disability is still too small to rule out idiosyncratic drug reaction.
Journal of intellectual disability research : JIDR, 1998 · doi:n/a